Navigation Links
Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share
Date:12/10/2010

/li>
  • The financing condition of the existing tender offer would be removed, including any requirement for future due diligence.
  • A seller-friendly second-step merger agreement with limited representations and warranties.
  • V&O Acquisition would be willing to close on the tender offer as soon as legally permissible, i.e., 10 business days after the announcement of the execution of the definitive merger agreement subject to Hart-Scott-Rodino ("HSR") approval.  V&O Acquisition is prepared to seek early termination of the waiting period under HSR.  V&O Acquisition is also prepared to reduce the 90% stock tender condition to 50.1% of the outstanding Common Stock upon execution of the merger agreement if the parties can negotiate an appropriate top-up option and subsequent offering period to facilitate a short-form second step merger.
  • V&O Acquisition is willing to provide a broad fiduciary out in the merger agreement for any higher or better offer received prior to the closing of the tender offer, with the breakup fee on the low end of fairness, i.e., two percent (2%) of transaction value.

  • Time is of the essence.  The above offer is subject to the condition that Cypress commences exclusive negotiations with V&O Acquisition no later than Friday, December 10, 2010 and enters into a definitive merger agreement by no later than Sunday, December 12, 2010.  

    V&O Acquisition appreciates that the Board of Directors and its financial advisors have fashioned a process by which Cypress has had the opportunity to fully explore strategic alternatives.  We believe stockholders are expecting the Board of Directors to bring this process to a prompt conclusion with a transaction that provides a high degree of certainty that they will receive immediate full and fair value for their shares.  The benefits of the Revised Offer should be clear to all concerned.


    '/>"/>
    SOURCE Ramius LLC
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Cypress Denies Ramius Legal Right to Stockholder List Materials
    2. UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America
    3. U of C scientist offers better ways to engineer Earths climate to prevent dangerous global warming
    4. Emerson Ecologics Exclusively Offers EcoNugenics ProstaCaid
    5. New paper offers breakthrough on blinking molecules phenomenon
    6. Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome
    7. Research from Rensselaer Polytechnic Institute professor offers clues to Alzheimers disease
    8. Carl Zeiss Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging
    9. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
    10. Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists
    11. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
    (Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
    (Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
    (Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
    Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2
    ... - Company to Host Conference Call at 4:30 p.m. ET ... PCYC ) today reported financial results for its fourth ... for the fourth quarter of,fiscal 2008 was $4.6 million, or ... or $0.27 per share, for the fourth quarter of fiscal ...
    ... is accelerating improvements for converting plant biomass into biofuelas ... needs, reports Eddy Rubin, Director of the U.S. Department ... August 14 edition of the journal Nature . ... a path forward for how emerging genomic technologies will ...
    ... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced that ... leading proxy advisory firms, have,recommended that SGX stockholders vote ... LLY ) at the SGX Special Stockholders Meeting,scheduled ... The Board of Directors of SGX unanimously recommends ...
    Cached Biology Technology:Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 2DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 3DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 4SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 2SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 3SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 4
    (Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
    (Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
    (Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
    Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
    ... influenza caused widespread death and illness in 1918, 1957, 1968 ... time of these pandemics finds that each of them was ... study,s authors--Jeffrey Shaman of Columbia University,s Mailman School of Public ... Healthnote that the La Nia pattern is known to alter ...
    ... new varieties of corn with a higher yield faster than ... Germany, and other institutions are relying on a trick: early ... chemical and genetic makeup, as well as on new statistical ... authoritative journal Nature Genetics on Sunday evening, Jan. ...
    ... proteins have characteristic ways of "walking," which (also like human ... have discovered the unique "drunken sailor" gait of dynein, a ... in the body and whose malfunction has been associated with ... The research, which was led by Samara Reck-Peterson ...
    Cached Biology News:Does the La Niña weather pattern lead to flu pandemics? 2Good parents are predictable -- at least when it comes to corn 2Good parents are predictable -- at least when it comes to corn 3Good parents are predictable -- at least when it comes to corn 4Walk this way: Scientists and MBL physiology students describe how a motor protein 'steps out' 2
    ... the principal excitatory neurotransmitter receptors ... glutamate receptors exist: Ionotropic receptors, ... receptors are oligomeric complexes of ... which comprise ligand-gated calcium channels. ...
    Recommended fro Western blotting application...
    ... KLF15 is a Cys2-His2 zinc finger gene. ... liver, kidneys, heart, and skeletal muscle. ... produced in rabbits immunized with a synthetic ... KLF15 with an internal ID of P03590 ...
    ... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
    Biology Products: